Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Acquired resistance to imatinib in gastrointestinal stromal tumours caused by multiple KIT mutations.

The Lancet. Oncology - 1 Apr 2005

Wardelmann Eva, Thomas Nadja, Merkelbach-Bruse Sabine, Pauls Katharina, Speidel Nicola, Büttner Reinhard, Bihl Heiner, Leutner Claudia C, Heinicke Thomas, Hohenberger Peter

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzamides
Share to Drug Resistance, Neoplasm
Share to Gastrointestinal Stromal Tumors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Imatinib Mesylate

Share to Neoplasm Metastasis

Share to Piperazines

Share to Proto-Oncogene Proteins c-kit

Share to Pyrimidines

Source

Identifiers

PMID: 15811621
DOI: 10.1016/S1470-2045(05)70097-8

Genes

KIT

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Acquired resistance to imatinib in gastrointestinal stromal tumours caused by multiple KIT mutations.PMID 15811621Read ↗

Two different KIT mutations may lead to different responses to imatinib in metastatic gastrointestinal stromal tumor.Semantic proximity Read ↗

Targeted therapy and personalized medicine in gastrointestinal stromal tumors: drug resistance, mechanisms, and treatment strategiesSemantic proximity Read ↗

Emerging Targeted Therapeutic Strategies to Overcome Imatinib Resistance of Gastrointestinal Stromal Tumors.Semantic proximity Read ↗

Targeted therapies in gastrointestinal stromal tumors.Semantic proximity Read ↗

Molecular Advances in the Treatment of Advanced Gastrointestinal Stromal Tumor.Semantic proximity Read ↗

Secondary C-kit mutation is a cause of acquired resistance to imatinib in gastrointestinal stromal tumor.Semantic proximity Read ↗

CCR 20th Anniversary Commentary: A Genetic Mechanism of Imatinib Resistance in Gastrointestinal Stromal Tumor-Where Are We a Decade Later?Semantic proximity Read ↗

KIT mutations and expression: current knowledge and new insights for overcoming IM resistance in GIST.Semantic proximity Read ↗

Nintedanib overcomes drug resistance from upregulation of FGFR signalling and imatinib-induced KIT mutations in gastrointestinal stromal tumours.Semantic proximity Read ↗

Current Drug Resistance Mechanisms and Treatment Options in Gastrointestinal Stromal Tumors: Summary and Update.Semantic proximity Read ↗

Systemic therapy for advanced gastrointestinal stromal tumors: beyond imatinib.Semantic proximity Read ↗

Mechanisms of secondary resistance to tyrosine kinase inhibitors in gastrointestinal stromal tumours (Review).Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.